Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Applicatio ...
In this video, Lukas Delasos, DO, discusses highlights from this year’s International Association for the Study of Lung ...
Acceptance of the New Drug Application is based on findings from a phase 2b portion of the open-label REZILIENT1 clinical trial.
The FDA has accepted a new drug application (NDA) for zipalertinib for the treatment of patients with locally advanced or ...
Patients diagnosed with metastatic breast cancer and non-small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...
The non-small cell lung cancer clinical trial analysis report delivers important insights into ongoing research of 120+ ...
The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. The Boston biotech has decided to discontinue a phase 1/2 trial in advanced KRAS G12C-mutated ...
HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...
Sacituzumab tirumotecan significantly reduced progression or death risk by 51% compared to chemotherapy in EGFR-mutated non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results